{"@context":{"@vocab":"https://cir.nii.ac.jp/schema/1.0/","rdfs":"http://www.w3.org/2000/01/rdf-schema#","dc":"http://purl.org/dc/elements/1.1/","dcterms":"http://purl.org/dc/terms/","foaf":"http://xmlns.com/foaf/0.1/","prism":"http://prismstandard.org/namespaces/basic/2.0/","cinii":"http://ci.nii.ac.jp/ns/1.0/","datacite":"https://schema.datacite.org/meta/kernel-4/","ndl":"http://ndl.go.jp/dcndl/terms/","jpcoar":"https://github.com/JPCOAR/schema/blob/master/2.0/"},"@id":"https://cir.nii.ac.jp/crid/1362825895519109760.json","@type":"Article","productIdentifier":[{"identifier":{"@type":"DOI","@value":"10.1046/j.1365-2893.2003.00437.x"}},{"identifier":{"@type":"URI","@value":"https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1046%2Fj.1365-2893.2003.00437.x"}},{"identifier":{"@type":"URI","@value":"https://onlinelibrary.wiley.com/doi/pdf/10.1046/j.1365-2893.2003.00437.x"}},{"identifier":{"@type":"PMID","@value":"12823601"}},{"identifier":{"@type":"NAID","@value":"30014687388"}}],"dc:title":[{"@value":"Clinical evaluation of a new enzyme immunoassay for hepatitis B virus core‐related antigen; a marker distinct from viral DNA for monitoring lamivudine treatment"}],"description":[{"type":"abstract","notation":[{"@value":"<jats:p><jats:bold>Summary.</jats:bold> We aimed to assess the clinical performance of a newly developed chemiluminescence enzyme immunoassay (CLEIA) for the detection of hepatitis B virus (HBV) core‐related antigen (HBcrAg) in patients with chronic HBV infection. A total of 82 patients with chronic HBV infection and 167 HBV‐negative controls were studied. HBcrAg was measured by CLEIA with monoclonal antibodies to hepatitis B e antigen (HBeAg) and hepatitis B core antigen (HBcAg), and HBV DNA was measured by transcription‐mediated amplification assay (TMA) and in‐house real‐time detection polymerase chain reaction (RTD‐PCR). The HBcrAg assay detected viremia in 189 of 216 samples (88%) collected from 72 patients whilst the TMA assay detected viremia in 178 of the 216 samples (82%) (<jats:italic>P</jats:italic> = 0.019). The HBcrAg concentration correlated linearly with the HBV DNA concentration (<jats:italic>P</jats:italic> < 0.001) over a range which varied 100 000‐fold. The accuracy in the measurement of the patients’ HBV load obtained using the HBcrAg assay was not affected by the absence of hepatitis B e antigen from the serum or the presence of precore mutations in the HBV genome. In patients without anti‐viral drugs, changes in their serum HBcrAg concentration over time corresponded to their HBV DNA concentration. In six additional patients who were later treated with lamivudine, HBV DNA concentration declined more rapidly than their HBcrAg concentration. Three months after treatment commenced, the ratio of HBcrAg: HBV DNA had increased in all six patients (<jats:italic>P</jats:italic> = 0.031). The HBcrAg assay is a sensitive and useful test for the assessment of a patient's HBV load. When monitoring the anti‐viral effect of lamivudine, HBcrAg provides a viral marker which is independent of HBV DNA.</jats:p>"}]}],"creator":[{"@id":"https://cir.nii.ac.jp/crid/1581980075972646272","@type":"Researcher","foaf:name":[{"@value":"A. Rokuhara"}]},{"@id":"https://cir.nii.ac.jp/crid/1382825895519109761","@type":"Researcher","foaf:name":[{"@value":"E. Tanaka"}]},{"@id":"https://cir.nii.ac.jp/crid/1382825895519109764","@type":"Researcher","foaf:name":[{"@value":"A. Matsumoto"}]},{"@id":"https://cir.nii.ac.jp/crid/1382825895519109763","@type":"Researcher","foaf:name":[{"@value":"T. Kimura"}]},{"@id":"https://cir.nii.ac.jp/crid/1382825895519109765","@type":"Researcher","foaf:name":[{"@value":"T. Yamaura"}]},{"@id":"https://cir.nii.ac.jp/crid/1382825895519109766","@type":"Researcher","foaf:name":[{"@value":"K. Orii"}]},{"@id":"https://cir.nii.ac.jp/crid/1382825895519109762","@type":"Researcher","foaf:name":[{"@value":"X. Sun"}]},{"@id":"https://cir.nii.ac.jp/crid/1382825895519109769","@type":"Researcher","foaf:name":[{"@value":"S. Yagi"}]},{"@id":"https://cir.nii.ac.jp/crid/1382825895519109767","@type":"Researcher","foaf:name":[{"@value":"N. Maki"}]},{"@id":"https://cir.nii.ac.jp/crid/1382825895519109760","@type":"Researcher","foaf:name":[{"@value":"K. Kiyosawa"}]}],"publication":{"publicationIdentifier":[{"@type":"PISSN","@value":"13520504"},{"@type":"EISSN","@value":"13652893"},{"@type":"PISSN","@value":"http://id.crossref.org/issn/13520504"}],"prism:publicationName":[{"@value":"Journal of Viral Hepatitis"}],"dc:publisher":[{"@value":"Wiley"}],"prism:publicationDate":"2003-06-23","prism:volume":"10","prism:number":"4","prism:startingPage":"324","prism:endingPage":"330"},"reviewed":"false","dc:rights":["http://onlinelibrary.wiley.com/termsAndConditions#vor"],"url":[{"@id":"https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1046%2Fj.1365-2893.2003.00437.x"},{"@id":"https://onlinelibrary.wiley.com/doi/pdf/10.1046/j.1365-2893.2003.00437.x"}],"createdAt":"2004-12-27","modifiedAt":"2023-10-13","foaf:topic":[{"@id":"https://cir.nii.ac.jp/all?q=Male","dc:title":"Male"},{"@id":"https://cir.nii.ac.jp/all?q=Hepatitis%20B%20virus","dc:title":"Hepatitis B virus"},{"@id":"https://cir.nii.ac.jp/all?q=Hepatitis%20B","dc:title":"Hepatitis B"},{"@id":"https://cir.nii.ac.jp/all?q=Hepatitis%20B%20Core%20Antigens","dc:title":"Hepatitis B Core Antigens"},{"@id":"https://cir.nii.ac.jp/all?q=Cohort%20Studies","dc:title":"Cohort Studies"},{"@id":"https://cir.nii.ac.jp/all?q=Immunoenzyme%20Techniques","dc:title":"Immunoenzyme Techniques"},{"@id":"https://cir.nii.ac.jp/all?q=Treatment%20Outcome","dc:title":"Treatment Outcome"},{"@id":"https://cir.nii.ac.jp/all?q=Lamivudine","dc:title":"Lamivudine"},{"@id":"https://cir.nii.ac.jp/all?q=Reference%20Values","dc:title":"Reference Values"},{"@id":"https://cir.nii.ac.jp/all?q=Case-Control%20Studies","dc:title":"Case-Control Studies"},{"@id":"https://cir.nii.ac.jp/all?q=DNA,%20Viral","dc:title":"DNA, Viral"},{"@id":"https://cir.nii.ac.jp/all?q=Humans","dc:title":"Humans"},{"@id":"https://cir.nii.ac.jp/all?q=Female","dc:title":"Female"},{"@id":"https://cir.nii.ac.jp/all?q=Biomarkers","dc:title":"Biomarkers"},{"@id":"https://cir.nii.ac.jp/all?q=Follow-Up%20Studies","dc:title":"Follow-Up Studies"},{"@id":"https://cir.nii.ac.jp/all?q=Monitoring,%20Physiologic","dc:title":"Monitoring, Physiologic"},{"@id":"https://cir.nii.ac.jp/all?q=Probability","dc:title":"Probability"}],"relatedProduct":[{"@id":"https://cir.nii.ac.jp/crid/1050022476722646656","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Sequential therapy involving an early switch from entecavir to pegylated interferon-α in Japanese patients with chronic hepatitis B"},{"@language":"ja-Kana","@value":"ニホンジン マンセイ Bガタ カンエン カンジャ ニオケル エンテカビル カラ ペグインターフェロンα エノ ソウキ キリカエ オ トモナウ チクジ リョウホウ"},{"@language":"ja","@value":"日本人慢性B型肝炎患者における、エンテカビルからペグインターフェロンαへの早期切り替えを伴う逐次療法"},{"@value":"Sequential therapy involving an early switch from entecavir to pegylated interferon‐α in Japanese patients with chronic hepatitis B"}]},{"@id":"https://cir.nii.ac.jp/crid/1050866901652671616","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Switching to tenofovir disoproxil fumarate vs continuing treatment in chronic hepatitis B patients who maintain long-term virological response to entecavir therapy: a randomized trial"},{"@value":"Switching to tenofovir disoproxil fumarate vs continuing treatment in patients with chronic hepatitis B who maintain long‐term virological response to entecavir therapy: A randomized trial"}]},{"@id":"https://cir.nii.ac.jp/crid/1360004231260693376","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Impact of alpha-fetoprotein on hepatocellular carcinoma development during entecavir treatment of chronic hepatitis B virus infection"}]},{"@id":"https://cir.nii.ac.jp/crid/1360004235525732352","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Hepatitis B virus (HBV)‐infected patients with low hepatitis B surface antigen and high hepatitis B core‐related antigen titers have a high risk of HBV‐related hepatocellular carcinoma"}]},{"@id":"https://cir.nii.ac.jp/crid/1360004237635771264","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"HBV preS deletion mapping using deep sequencing demonstrates a unique association with viral markers"}]},{"@id":"https://cir.nii.ac.jp/crid/1360017287044244224","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Drug Discovery Study Aimed at a Functional Cure for HBV"}]},{"@id":"https://cir.nii.ac.jp/crid/1360283692546753920","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Hepatitis B Virus (HBV) Core-Related Antigen During Nucleos(t)ide Analog Therapy Is Related to Intra-hepatic HBV Replication and Development of Hepatocellular Carcinoma"}]},{"@id":"https://cir.nii.ac.jp/crid/1360285707527549184","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Cross-species transmission of gibbon and orangutan hepatitis B virus to uPA/SCID mice with human hepatocytes"}]},{"@id":"https://cir.nii.ac.jp/crid/1360285709456608384","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Long-Term Outcome of Sequential Therapy with Lamivudine Followed by Interferon-β in Nucleoside-Naive, Hepatitis B e-Antigen-Positive Patients with Chronic Hepatitis B Virus Genotype C Infection"}]},{"@id":"https://cir.nii.ac.jp/crid/1360290617881823744","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Clinical efficacy of a novel, high-sensitivity HBcrAg assay in the management of chronic hepatitis B and HBV reactivation"}]},{"@id":"https://cir.nii.ac.jp/crid/1360294740589267968","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Clinical usefulness of a novel high-sensitivity hepatitis B core-related antigen assay to determine the initiation of treatment for HBV reactivation"}]},{"@id":"https://cir.nii.ac.jp/crid/1360302866851404928","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Hepatitis B core-related antigen: A novel and promising surrogate biomarker to guide anti-hepatitis B virus therapy"}]},{"@id":"https://cir.nii.ac.jp/crid/1360306905172752256","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Prediction of cccDNA dynamics in hepatitis B patients by a combination of serum surrogate markers"}]},{"@id":"https://cir.nii.ac.jp/crid/1360565165280107648","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Serum Wisteria floribunda agglutinin-positive Mac-2 binding protein predicts hepatocellular carcinoma incidence and recurrence in nucleos(t)ide analogue therapy for chronic hepatitis B"}]},{"@id":"https://cir.nii.ac.jp/crid/1360565168116348928","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"JSH Guidelines for the Management of Hepatitis B Virus Infection"}]},{"@id":"https://cir.nii.ac.jp/crid/1360567180140804864","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Impact of peginterferon alpha‐2b and entecavir hydrate combination therapy on persistent viral suppression in patients with chronic hepatitis B"}]},{"@id":"https://cir.nii.ac.jp/crid/1360848656190200320","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Entecavir and interferon-α sequential therapy in Japanese patients with hepatitis B e antigen-positive chronic hepatitis B"}]},{"@id":"https://cir.nii.ac.jp/crid/1360848660687497728","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Treatment of chronic hepatitis B with nucleos(t)ide analogues"}]},{"@id":"https://cir.nii.ac.jp/crid/1360848660687642496","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Anti‐hepatitis B virus therapy: To stop, or not to stop: Has the question been solved?"}]},{"@id":"https://cir.nii.ac.jp/crid/1360853567500721664","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Sequential therapy from entecavir to tenofovir alafenamide <i>versus</i> continuous entecavir monotherapy for patients with chronic hepatitis B"}]},{"@id":"https://cir.nii.ac.jp/crid/1390282679771619840","@type":"Article","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Two cases of acute hepatitis due to hepatitis E virus that are indigenous to Kitakyushu: a case report"},{"@language":"ja","@value":"北九州に土着したE型肝炎ウイルス株による急性肝炎の2例"},{"@value":"B型肝炎治療ガイドライン(第1.1版)"},{"@language":"ja-Kana","@value":"Bガタ カンエン チリョウ ガイドライン(ダイ1.1ハン)"},{"@language":"ja-Kana","@value":"キタキュウシュウ ニ ドチャク シタ Eガタ カンエンウイルスカブ ニ ヨル キュウセイ カンエン ノ 2レイ"},{"@value":"Guidelines for the management of hepatitis B virus infection"}]},{"@id":"https://cir.nii.ac.jp/crid/1390282679848799616","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"The Significance of Enzyme Immunoassay for the Assessment of Hepatitis B Virus Core-Related Antigen following Liver Transplantation"}]},{"@id":"https://cir.nii.ac.jp/crid/1390303465375510528","@type":"Article","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Current global applications of HBcrAg assays in the management of chronic hepatitis B"}]},{"@id":"https://cir.nii.ac.jp/crid/1520290884527067136","@type":"Article","relationType":["isCitedBy"],"jpcoar:relatedTitle":[{"@value":"ルミパルスfを用いたB型肝炎ウイルスコア関連抗原(HBcrAg)測定法の基礎的・臨床的検討"},{"@language":"ja-Kana","@value":"ルミパルス f オ モチイタ Bガタ カンエン ウイルスコア カンレン コウゲン HBcrAg ソクテイホウ ノ キソテキ リンショウテキ ケントウ"}]},{"@id":"https://cir.nii.ac.jp/crid/1570009750461422976","@type":"Article","relationType":["isCitedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Measurement of hepatitis B virus core-related antigen as predicting factor for relapse after cessation of lamivudine therapy for chronic hepatitis B virus infection"}]},{"@id":"https://cir.nii.ac.jp/crid/1571980075939746432","@type":"Article","relationType":["isCitedBy"],"jpcoar:relatedTitle":[{"@language":"ja","@value":"HBV-DNA測定におけるコバスTaqManHBV「オート」の基礎的および臨床的評価"},{"@language":"en","@value":"Fundamental and Clinical Evaluation of the COBAS AmpliPrep/COBAS TaqMan HBV Test for the Detection of Hepatitis B Virus (HBV)-DNA"}]},{"@id":"https://cir.nii.ac.jp/crid/1573668925182462464","@type":"Article","relationType":["isCitedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Hepatitis B virus RNA is measurable in serum and can be a new marker for monitoring lamivudine therapy"}]}],"dataSourceIdentifier":[{"@type":"CROSSREF","@value":"10.1046/j.1365-2893.2003.00437.x"},{"@type":"CIA","@value":"30014687388"},{"@type":"OPENAIRE","@value":"doi_dedup___::ed1dae131f664992960b85f1f3038f4a"},{"@type":"CROSSREF","@value":"10.1007/s00535-014-1010-7_references_DOI_AfIWPnct0nsMNgG8243gwI2iQQ"},{"@type":"CROSSREF","@value":"10.1111/hepr.13277_references_DOI_AfIWPnct0nsMNgG8243gwI2iQQ"},{"@type":"CROSSREF","@value":"10.1371/journal.pone.0212559_references_DOI_AfIWPnct0nsMNgG8243gwI2iQQ"},{"@type":"CROSSREF","@value":"10.3390/v14071393_references_DOI_AfIWPnct0nsMNgG8243gwI2iQQ"},{"@type":"CROSSREF","@value":"10.1093/infdis/jiv572_references_DOI_AfIWPnct0nsMNgG8243gwI2iQQ"},{"@type":"CROSSREF","@value":"10.1089/jir.2014.0234_references_DOI_AfIWPnct0nsMNgG8243gwI2iQQ"},{"@type":"CROSSREF","@value":"10.1016/j.jhep.2021.02.017_references_DOI_AfIWPnct0nsMNgG8243gwI2iQQ"},{"@type":"CROSSREF","@value":"10.1007/s00535-022-01872-w_references_DOI_AfIWPnct0nsMNgG8243gwI2iQQ"},{"@type":"CROSSREF","@value":"10.3350/cmh.2022.0434_references_DOI_AfIWPnct0nsMNgG8243gwI2iQQ"},{"@type":"CROSSREF","@value":"10.1111/hepr.13050_references_DOI_AfIWPnct0nsMNgG8243gwI2iQQ"},{"@type":"CROSSREF","@value":"10.1371/journal.pcbi.1012615_references_DOI_AfIWPnct0nsMNgG8243gwI2iQQ"},{"@type":"CROSSREF","@value":"10.1007/s00535-017-1386-2_references_DOI_AfIWPnct0nsMNgG8243gwI2iQQ"},{"@type":"CROSSREF","@value":"10.1111/hepr.12269_references_DOI_AfIWPnct0nsMNgG8243gwI2iQQ"},{"@type":"CROSSREF","@value":"10.1002/jmv.23564_references_DOI_AfIWPnct0nsMNgG8243gwI2iQQ"},{"@type":"CROSSREF","@value":"10.35772/ghm.2024.01097_references_DOI_AfIWPnct0nsMNgG8243gwI2iQQ"},{"@type":"CROSSREF","@value":"10.1007/s00535-012-0645-5_references_DOI_AfIWPnct0nsMNgG8243gwI2iQQ"},{"@type":"CROSSREF","@value":"10.1111/j.1872-034x.2011.00921.x_references_DOI_AfIWPnct0nsMNgG8243gwI2iQQ"},{"@type":"CROSSREF","@value":"10.1111/j.1872-034x.2012.01001.x_references_DOI_AfIWPnct0nsMNgG8243gwI2iQQ"},{"@type":"CROSSREF","@value":"10.2957/kanzo.54.402_references_DOI_AfIWPnct0nsMNgG8243gwI2iQQ"},{"@type":"CROSSREF","@value":"10.2169/internalmedicine.48.2000_references_DOI_AfIWPnct0nsMNgG8243gwI2iQQ"},{"@type":"CROSSREF","@value":"10.1016/j.virusres.2011.04.002_references_DOI_AfIWPnct0nsMNgG8243gwI2iQQ"},{"@type":"CROSSREF","@value":"10.1002/jgh3.12443_references_DOI_AfIWPnct0nsMNgG8243gwI2iQQ"},{"@type":"CROSSREF","@value":"10.1002/jmv.25442_references_DOI_AfIWPnct0nsMNgG8243gwI2iQQ"}]}